Obesity and the Kidney

Editor(s): Wolf, G. (Jena)
 

Body Mass Index and the Risk of Chronic Renal Failure: The Asian Experience

Iseki K.

Author affiliations

Dialysis Unit, University Hospital of The Ryukyus, Okinawa, Japan

Related Articles for ""

Wolf G (ed): Obesity and the Kidney. Contrib Nephrol. Basel, Karger, 2006, vol 151, pp 42-56

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: August 21, 2006
Cover Date: 2006

Number of Print Pages: 15
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-8164-6 (Print)
eISBN: 978-3-318-01384-9 (Online)

Abstract

Background: There is a worldwide obesity epidemic, and the number of patients requiring dialysis because of obesity-related renal disease such as diabetes mellitus and hypertension is increasing. Obesity increases the risk of cardiovascular disease and premature death due to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Although the effect of obesity might differ among races, obesity has a significant impact on CKD and ESRD. Methods: We examined the relationship between obesity (i.e., body mass index [BMI]) and CKD or ESRD using a community based screening registry in Okinawa, Japan. For this purpose, we used a general screening registry (1983, 1993, and 2003), the ESRD patient registry (1971-2000), a hospital-based cardiovascular disease registry (1988-1990), and a hospital-based screening registry (2003). Results: The prevalence of obesity, based on a BMI ≥ 30 kg/m2, was 3.5% (1983), 4.7% (1993), and 6.2% (2003) in the general adult population. The incidence of ESRD increased when BMI increased, particularly in men. In the hospital-based screening study, the number of components of metabolic syndrome was significantly related with the prevalence of CKD. The relationship was linear when the modified National Cholesterol Education Program criteria were used to define abdominal obesity as a waist circumference of 85 cm or more in men and 90 cm or more in women. Conclusion: Although prospective studies are needed, our findings indicate that obesity, including metabolic syndrome, is a potential treatable cause of CKD and ESRD. Rigorous efforts should be made to optimize weight to reduce the risk of CKD and ESRD by a judicious combination of diet, exercise, and psychologic therapies.




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: August 21, 2006
Cover Date: 2006

Number of Print Pages: 15
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-8164-6 (Print)
eISBN: 978-3-318-01384-9 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP